Coya Therapeutics
Open
$4.24
Prev. Close
$4.24
High
$4.26
Low
$4.24
Market Snapshot
$85.16M
-4.0
-1.07
$3.69M
8
Coya Therapeutics, Inc. is a clinical-stage biotechnology company which engages in developing proprietary medicinal products to modulate the function of regulatory T cells. The company is headquartered in Houston, Texas and currently employs 8 full-time employees. The company went IPO on 2022-12-29. Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet medical need. Its diversified candidate pipeline includes both ex vivo and in vivo approaches. Its product candidate pipeline is based on its three therapeutic modalities. The product candidates utilizing its Treg-enhancing biologics are collectively referred to as the 300 Series. The product candidates utilizing its Treg-derived exosomes are collectively referred to as the 200 Series. The product candidates utilizing its autologous Treg cell therapy are collectively referred to as the 100 Series. The firm's 300 Series product candidates include COYA 301 and COYA 302.
emptyResult
Coya Therapeutics, Inc. is a clinical-stage biotechnology company which engages in developing proprietary medicinal products to modulate the function of regulatory T cells. The company is headquartered in Houston, Texas and currently employs 8 full-time employees. The company went IPO on 2022-12-29. Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet medical need. Its diversified candidate pipeline includes both ex vivo and in vivo approaches. Its product candidate pipeline is based on its three therapeutic modalities. The product candidates utilizing its Treg-enhancing biologics are collectively referred to as the 300 Series. The product candidates utilizing its Treg-derived exosomes are collectively referred to as the 200 Series. The product candidates utilizing its autologous Treg cell therapy are collectively referred to as the 100 Series. The firm's 300 Series product candidates include COYA 301 and COYA 302.
Recently from Cashu
Coya Therapeutics Innovates Treg-Enhancing Biologics for Neurodegenerative Disease Treatment
Coya Therapeutics Focuses on Innovative Treg-Enhancing Biologics Coya Therapeutics, Inc., a Houston-based biotechnology firm, is at the forefront of developing biologics that enhance regulatory T cell…
Coya Therapeutics Focuses on Treg Biologics for Neurodegenerative Disease Treatment Advancements
Coya Therapeutics Enhances Focus on Treg-based Biologics for Neurodegenerative Diseases Coya Therapeutics, Inc., a Houston-based biotechnology company, is making significant strides in the development…
Coya Therapeutics Advances COYA 303: Innovative Therapy for Inflammatory Diseases
Coya Therapeutics Advances Innovative Immunomodulatory Therapy COYA 303 Coya Therapeutics, Inc., a Houston-based clinical-stage biotechnology company, is making significant strides in its investigatio…
Coya Therapeutics Advances COYA 303: Innovative Treatment for Inflammatory Diseases in Development
Coya Therapeutics Advances COYA 303: A Promising Therapeutic for Inflammatory Diseases Coya Therapeutics, Inc., a Houston-based clinical-stage biotechnology company, is making strides in the developme…